It is not every year that a cancer treatment earns the label “first in the world,” and the label itself deserves a careful look. On June 22, 2026, China’s National Medical Products Administration approved satricabtagene autoleucel, or satri-cel, from Shanghai-based CARsgen Therapeutics. CARsgen says it is the first CAR T-cell therapy approved for a solid tumor.
For all the noise around immunotherapy, the salient point is narrow. The approval covers one disease and one biomarker-defined group of patients.
A hard disease
Gastric cancer ranks fifth in both incidence and mortality worldwide, with roughly 970,000 new cases and 660,000 deaths a year, according to figures cited by CARsgen. More than 70% of cases occur in Asia, and Chinese patients make up about 47% of the global burden. The National Cancer Center of China counted about 360,000 new cases and 260,000 deaths in the country in 2022.
The disease is insidious. In China, early-stage diagnosis stays below 20%, and the five-year survival rate for advanced gastric cancer is about 10%. Conventional chemotherapy has plateaued, and targeted options are limited.
Why solid tumors were harder
CAR T therapy has been one of oncology’s success stories for over a decade, almost entirely in blood cancers such as leukemia and lymphoma. Solid tumors, which make up most cancer cases, stayed out of reach. They hide behind dense protective tissue, create an immune-suppressing environment around themselves, and often lack a single uniform marker that sits on tumor cells but not on healthy ones.
The method is the same in every case. Doctors draw a sample of the patient’s own T-cells and re-engineer them in a lab to recognize a marker on cancer cells. The cells are multiplied into the millions and infused back.
Satri-cel’s marker is Claudin18.2, a protein found on the surface of many gastric and pancreatic cancer cells and only in very limited amounts on healthy tissue. That selectivity, CARsgen says, is what makes it workable as a target. CARsgen also claims to have been the first to validate it for CAR T therapy.
Who it is for
Marketed as Kaileimei, the therapy is indicated for adults with advanced Claudin18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma who have failed at least two prior lines of treatment. Tumors must be tested for both markers, so plenty of gastric cancer patients will not qualify. Notably, this is a later-line option, not a replacement for earlier treatment. Until now, such patients faced mostly further chemotherapy with modest expected benefit.
The support comes from a randomized, open-label phase 2 trial that compared satri-cel with physician’s choice of treatment in previously treated patients. The Lancet published the results in 2025. CARsgen says the therapy showed significant efficacy and a good safety profile against existing treatments. Professor Lin Shen of Peking University Cancer Hospital, whose team led the studies, said it offers patients a chance to escape frequent hospital visits, a leap “from ‘prolonging survival’ to ‘improving quality of life.’”
Caution is still in order. It is not a cure, and risks typical of CAR T therapy, including cytokine release syndrome and neurological effects, call for a center experienced in managing them. CARsgen and Chinese health authorities were still finalizing label details, the full safety profile and pricing. The company is testing the drug in earlier lines and after surgery, including a phase I trial in pancreatic cancer. For now it is approved only in China, and availability elsewhere has not been confirmed.
Sources
- Newsroom
- China Approves Satri-Cel: World's First CAR T-Cell Therapy for a Solid Tumor
- Latest Solid Tumor CAR-T Treatments Available in China
- Satri-cel in China: CLDN18.2 Gastric Cancer Access Pathways
Photo: Navy Medicine / Unsplash (Unsplash License)
